Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Y-Mabs Therapeutics Inc (YMAB)

Y-Mabs Therapeutics Inc (YMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 391,221
  • Shares Outstanding, K 45,438
  • Annual Sales, $ 87,690 K
  • Annual Income, $ -29,670 K
  • EBIT $ -27 M
  • EBITDA $ -26 M
  • 60-Month Beta 0.53
  • Price/Sales 4.45
  • Price/Cash Flow N/A
  • Price/Book 4.46
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.50
  • Most Recent Earnings $-0.07 on 08/08/25
  • Next Earnings Date 11/14/25
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate -0.23
  • Number of Estimates 5
  • High Estimate -0.19
  • Low Estimate -0.30
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -43.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.51 +1.16%
on 08/18/25
8.61 unch
on 09/15/25
+0.09 (+1.06%)
since 08/15/25
3-Month
3.90 +120.77%
on 06/20/25
8.61 unch
on 09/15/25
+3.90 (+82.80%)
since 06/13/25
52-Week
3.55 +142.54%
on 05/15/25
16.11 -46.55%
on 11/07/24
-5.13 (-37.34%)
since 09/13/24

Most Recent Stories

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DNOW, TASK, YMAB on Behalf of Shareholders

NEW YORK , Aug. 18, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

TASK : 10.46 (+0.48%)
DNOW : 16.38 (+1.30%)
YMAB : 8.61 (+0.23%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAA, YMAB, DNOW on Behalf of Shareholders

NEW YORK , Aug. 12, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

DNOW : 16.38 (+1.30%)
STAA : 17.85 (+1.65%)
YMAB : 8.61 (+0.23%)
Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders

The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breaches of fiduciary duty and other violations of law in its transaction with SERB Pharmaceuticals . ...

YMAB : 8.61 (+0.23%)
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company’s guidance range of between $17 million and $19 million SERB Pharmaceuticals to acquire...

YMAB : 8.61 (+0.23%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, YMAB, HLVX on Behalf of Shareholders

NEW YORK , Aug. 8, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

ARIS : 19.31 (-18.49%)
HLVX : 2.09 (-0.48%)
YMAB : 8.61 (+0.23%)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)

NEW YORK , Aug. 7, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"),...

YMAB : 8.61 (+0.23%)
Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Y-mAbs Therapeutics...

YMAB : 8.61 (+0.23%)
Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development...

YMAB : 8.61 (+0.23%)
Shareholder Alert: The Ademi Firm investigates whether Y-mAbs Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , Aug. 5, 2025 /PRNewswire/ -- The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breaches of fiduciary duty and other violations of law in its transaction with...

YMAB : 8.61 (+0.23%)
YMAB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Y-mAbs Therapeutics, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) to SERB Pharmaceuticals for $8.60 per share in cash is fair to Y-mAbs shareholders....

YMAB : 8.61 (+0.23%)

Business Summary

Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company's product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics...

See More

Key Turning Points

3rd Resistance Point 8.64
2nd Resistance Point 8.62
1st Resistance Point 8.62
Last Price 8.61
1st Support Level 8.60
2nd Support Level 8.58
3rd Support Level 8.58

See More

52-Week High 16.11
Fibonacci 61.8% 11.31
Fibonacci 50% 9.83
Last Price 8.61
Fibonacci 38.2% 8.35
52-Week Low 3.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar